FDA Approves Ogivri (trastuzumab-dkst), a Biosimilar to Herceptin

December 1, 2017 -- The U.S. Food and Drug Administration today approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news